The relation between the inflammatory cytokine tumour necrosis factor-cc (TNF or cachectin), which induces acute phase responses, and an established acute phase protein, C-reactive protein, was studied in various infectious and inflammatory diseases in man. All cases with very high serum concentrations of C-reactive protein (150 to 400 mg/I; normal reference value < 10 mg/i) also had raised serum concentrations of TNF (53 to 705 ng/l; normal reference value < 40 ng/l). In 19 out of 91 (21%) of the cases, however, a raised TNF concentration without correspondingly raised Creactive protein concentration was also noted. Conversely, in 23 out of 106 (22%) cases raised Creactive protein was observed in the absence of a raised TNF concentration. The ratios were high in allograft rejection and low in myocardial infarction and Kawasaki's disease. The highest mean concentration of circulating TNF was found in bacterial infections, graft rejection, and myocardial infarction.
raised TNF concentrations, there are pronounced relative variations in the serum concentrations of these proteins in various disease states, suggesting that there may be independent, disease specific regulatory pathways for TNF and C-reactive protein.
Tumour necrosis factor-a (TNF or cachectin) is a hormone-like intercellular signal peptide with a role in host defence processes against tumour cell growth and parasite infection. Recent studies have also implicated TNF in the regulation of normal cell metabolism and as an effector molecule in various processes related to inflammation.'2 TNF is elaborated mainly by cells of the mononuclear phagocyte system and induces several phenomena associated with the acute phase response such as fever, granulocyte activation, and hepatic protein synthesis. Raised concentrations of circulating TNF in certain inflammatory diseases have recently been reported.?' To gain insight into the association between circulating TNF and the acute phase response in disease, TNF was measured in various pathological conditions and compared with the concentration of C-reactive protein, and in some instances, also with serum amyloid A protein (SAA), acute phase proteins known to be produced by the liver.
Accepted for publication 25 May 1989 Patients and methods Cross sectional studies were carried out in 139 patients with rheumatoid arthritis (n = 22), systemic lupus erythematosus (n = 17), Kawasaki's disease (n = 39), myocardial infarction (n = 10), renal allograft rejection (n = 9), human immunodeficiency virus (HIV) infection (n = 21) or systemic bacterial diseases (n = 21). Serum samples from 40 healthy blood donors served as controls.
Longitudinal studies were carried out in cases of myocardial infarction (1 1, 15, and 19 samples, respectively/patient), renal allograft rejection (23 and 24 samples, respectively/patient), Gram negative septicaemia (12 samples/patient), AIDS (six samples/ patient), Crohn's disease (eight samples/patient) and histiocytosis (11 samples/patient).
TNF in serum was measured using a sensitive double antibody radioimmunoassay.'2 The detection limit of the assay is 7 ng/l. To calculate the intra-assay and interassay coefficients of variation sera were analysed over 26 days in three parallel determinations in nine separate assays for the interassay assessment, and in 10 to 15 parallel measurements, each in one run, for intra-assay precision. The intra-assay and interassay coefficients of variation were 8-2% and 9 4%, respectively, for a TNF concentration of 15 ng/l, and 6-3% and 7 0%, respectively, for a concentration of 92 ng/l. The concentrations ofTNF in healthy subjects (40 blood donors) was less than 40 ng/l. C-reactive protein was measured by radial immunodiffusion using specific antiserum (Orion Diagnostica, Finland) and C-reactive protein reference serum (Behringwerke AG, West Germany) as standard. The C-reactive protein concentration in healthy subjects (40 blood donors) was less than 10 mg/l. SAA was measured by radial immunodiffusion as described before.'3 Normal reference values of SAA are < 15 mg/1. '4 Results were expressed as mean i standard error of mean, and as ranges. Correlation coefficients (r) were calculated using linear regression analysis.
Results
Serum TNF concentrations were highest in bacterial infections (327 (93) ng/l, renal allograft rejection (159 (34) ng/l), and myocardial infarction (129 (32) ng/l).
The concentrations of TNF in rheumatoid arthritis (104 (25) ng/l) and in HIV infection (74 (16) ng/l) were moderately raised; the mean TNF concentrations in systemic lupus erythematosus were within the normal reference range (table 1) . A tendency towards a corresponding TNF concentrations was weak. This finding was also reflected in the pronounced variation in the relative TNF C-reactive protein ratios in disease. The ratio was high in immunological tissue injury (renal allograft rejection)-high TNF and low C-reactive protein responses. In contrast, tissue injury in association with myocardial infarction was characterised by low TNF: C-reactive protein ratios.
In 21% of the cases raised TNF concentrations was observed in the absence of an increased C-reactive protein concentration; most of these cases were associated with immunological tissue injury. Conversely, in 22% a raised C-reactive protein concentration was found in the absence of raised TNF; these occurred in different diseases including bacterial infections and rheumatoid arthritis.
Our results show that the TNF response in inflammation is disease specific and differs in several respects from the C-reactive protein response. Activation of monocytes and macrophages,'2 and possibly other cells as well,24 is the primary event which initiates TNF production. Experimental studies show that a wide range of infectious and non-infectious agents can activate mononuclear phagocytes. Interestingly, the gene coding for TNF has been mapped to chromosome 6 in close linkage to the major histocompatibility genes.25 The finding of abnormal TNF expression in conditions characterised by dysfunction of the regulation of the immune system is not, therefore, surprising.
TNF induces the synthesis of hepatic acute phase proteins by modulating gene expression during the acute phase response. TNF, however, is not the only humoral factor involved. Interleukin 126 and interleukin 6232728 also induce acute phase protein synthesis. The relative roles and possible interaction of the various cytokines in inducing C-reactive protein synthesis in man is not known, but the pronounced differences in C-reactive protein responses at certain Monitoring the acute phase response TNF concentrations suggest that mediators other than TNF may also be implicated.
The different TNF:CRP ratios resulting from various acute inflammatory stimuli may also be explained by differences in consumption and clearance from the circulation. Anti-inflammatory and immunosuppressive drugs may also affect the metabolism of TNF and C-reactive protein differently. Using a bioassay for serum TNF, Waage et al have calculated that the half-life of TNF is about 70 minutes in patients with meningococcal septic shock.29 In cancer patients receiving intravenous recombinant TNF, the half-life in blood was estimated at 20 minutes.30 Data from studies on mice3' and rats32 show a great variation of the measured half-lives of SAA, depending probably both on experimental design and species difference. The in vivo half-life of labelled C-reactive protein in the circulation of rabbits has been reported to be four to six hours. 33 In man serial measurements of the serum concentrations of SAA and C-reactive protein following tissue injury' and ethiocholanolone administration,35 however, show that the kinetics of these proteins are similar. Our results show that the kinetics of the TNF and SAA and C-reactive protein responses following tissue injury are also rather similar, though the correlation between TNF and Creactive protein is considerably weaker than the correlation between C-reactive protein and SAA under these conditions. 
